ArticleAmerican journal of clinical and experimental immunology2024
Heat shock protein 70 gene polymorphisms in Iranian patients with Multiple sclerosis.
Article in American journal of clinical and experimental immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic factors are effective reagents in susceptibility to multiple sclerosis (MS). Previous studies have shown the relationship between heat shock protein (HSP) gene polymorphisms. So, HSP70 single nucleotide polymorphisms (SNPs) were evaluated as MS risk factors. Here, DNA genotyping was done for HSP70 gene polymorphisms, including HSP70-1 +190 G>C, HSP70-1 -110 A>C, HSP70-1 +438 A>C, and HSP70-hom +2437 A>G in two groups including Iranian MS patients and controls. A standard phenol/chloroform method isolated DNA samples from peripheral blood. Sequence-specific amplification (SSP) polymerase chain reaction (PCR) was used for genotyping polymorphisms. Overall, 76 (35.80%) MS patients and 136 (65.10%) controls were studied with an age mean of 36.0 ± 8.0 years. Female/male was significantly higher in patients than in controls (4.43 vs. 0.10,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.